Inferra AI / Company / WST
West Pharmaceutical Services
WST · Health Care
Last earnings Oct 29, 2026
Key results
EPSquarter
$1.92
Diluted EPS of $1.92, compared to $1.85 in the same period last year.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Adjusted EPSquarter
$1.96
Adjusted-diluted EPS of $1.96, compared to $1.85 in the same period last year.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Products Segment Net revenuequarter
$647.5 million
Proprietary Products Segment Net sales of $647.5 million grew by 7.7% and increased 5.1% on an organic basis.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Contract-Manufactured Products Segment Net sales of $157.1 million increased by 8.0% and rose 4.9% on an organic basis.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Capexquarter
$293.9 million
Free cash flow (defined as operating cash flow minus capital expenditures) was $293.9 million, an increase of 53.7% over the same period last year.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Net incomequarter
$ 140.0
net income of affiliated companies (2.1) (3.9) (10.5) (1) (12.7) Net income $ 140.0
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Segment Organic Net revenuequarter
$1,830.3
GAAP) (3) 2025 2024 Proprietary Products $1,830.3 $1,720.6 6.4 % 1.1 % 5.3 % Contract-Manufactured Products 438.8 423.8 3.5 % 1.4 % 2.1 % Total $2,269.1 $2,144.4 5.8 % 1.1 % 4.7 % Reconciliation of Proprietary Products Segment Organic Net Sales by Product Category (3) Three Months ended September 30, Reported Net Sales (U.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
GAAP) (3) 2025 2024 HVP Components $1,061.2 $980.9 8.2 % 1.3 % 6.9 % HVP Delivery Devices 296.0 271.6 9.0 % 0.6 % 8.4 % Standard Products 473.1 468.1 1.1 % 0.9 % 0.2 % Total Proprietary Products $1,830.3 $1,720.6 6.4 % 1.1 % 5.3 % Reconciliation of Proprietary Products Segment Organic Net Sales by Market Group (3) Three Months ended September 30, Reported Net Sales (U.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
AI analysis
Q3 2025 · reported Oct 23, 2025
Based on: Earnings release + Q3 2025 deck + parent 8-K — transcript not held
+5.9% vs year ago computed from stated figures
The quarter in charts
Diluted EPS — GAAP
Per diluted share, as stated
EX-99 · Oct 23, 2025 EPS values as stated in the release.
Headline figures
| Metric | Q3 2025 | Prior qtr | Year ago |
|---|---|---|---|
| EPS | $1.92 | $1.82 | $1.85 |
| Adjusted EPS | $1.96 | $1.82 | $1.85 |
| Products Segment Net revenue | $647.5 million | — | — |
| Capex | $293.9 million | $160.0 million | — |
| Net income | $ 140.0 | — | — |
| Segment Organic Net revenue | $1,830.3 | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Exhibit 99.1 West Reports Third-Quarter 2025 Results - Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components - - Strengthened executive leadership team, including recently appointed CFO Robert McMahon - - Increases Full-Year 2025 Revenue and EPS Guidance - Exton, PA, October 23, 2025 West Pharmaceutical Services, Inc.”
“Full-year 2025 adjusted-diluted EPS guidance increased to a range of $7.06 to $7.11 , up from $6.65 to $6.85.”
“Full-Year 2025 Financial Guidance The Company is increasing its full-year 2025 net sales guidance range to $3.060 billion to $3.070 billion , up from $3.040 billion to $3.060 billion.”
“The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $7.06 to $7.11 , up from the previous range of $6.65 to $6.85.”
“Adjusted-diluted EPS guidance assumes a $0.27 benefit based on current foreign exchange rates, unchanged from previous guidance.”
“Capital spending guidance is unchanged at $275 million.”
Classified from the release's primary full-year outlook statement.
Cash flow & capex
Capital allocation
Capital expenditures were $209.8 million, a decrease of 22.9% over the same period last year.
Event summary
Green, President, Chief Executive Officer and Chair of the Board, commented I am pleased to report that we delivered another solid quarter, with both revenues and profits exceeding our guidance
Based on: Earnings release + Q3 2025 deck + parent 8-K — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document Exhibit 99.1 West Reports Third-Quarter 2025 Results - Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components - - Strengthened executive leadership team, including recently appointed CFO Robert McMahon - - Increases Full-Year 2025 Revenue and EPS Guidance - Exton, PA, October 23, 2025 West Pharmaceutical Services, Inc.”
EPS: “Full-year 2025 adjusted-diluted EPS guidance increased to a range of $7.06 to $7.11 , up from $6.65 to $6.85.”
Revenue: “Full-Year 2025 Financial Guidance The Company is increasing its full-year 2025 net sales guidance range to $3.060 billion to $3.070 billion , up from $3.040 billion to $3.060 billion.”
EPS: “The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $7.06 to $7.11 , up from the previous range of $6.65 to $6.85.”
EPS: “Adjusted-diluted EPS guidance assumes a $0.27 benefit based on current foreign exchange rates, unchanged from previous guidance.”
Company outlook: “Capital spending guidance is unchanged at $275 million.”
Revenue — Raised (“Increases”)
“htm EX-99.1 Document Exhibit 99.1 West Reports Third-Quarter 2025 Results - Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components - - Strengthened executive leadership team, including recently appointed CFO Robert McMahon - - Increases Full-Year 2025 Revenue and EPS Guidance - Exton, PA, October 23, 2025 West Pharmaceutical Services, Inc.”
EPS — Raised (“increased”)
“Full-year 2025 adjusted-diluted EPS guidance increased to a range of $7.06 to $7.11 , up from $6.65 to $6.85.”
Company outlook — Raised (“increasing”)
“As a result of the solid performance in the quarter, and the ongoing momentum in our business, we are again increasing our full-year guidance expectations.”
Revenue — Raised (“increasing”)
“Full-Year 2025 Financial Guidance The Company is increasing its full-year 2025 net sales guidance range to $3.060 billion to $3.070 billion , up from $3.040 billion to $3.060 billion.”
EPS — Raised (“increasing”)
“The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $7.06 to $7.11 , up from the previous range of $6.65 to $6.85.”
EPS — Reiterated (“unchanged”)
“Adjusted-diluted EPS guidance assumes a $0.27 benefit based on current foreign exchange rates, unchanged from previous guidance.”
Company outlook — Reiterated (“unchanged”)
“Capital spending guidance is unchanged at $275 million.”
Revenue — Initiated (“introducing”)
“Fourth-Quarter 2025 Financial Guidance The Company is introducing its fourth-quarter 2025 net sales guidance range of $790 million to $800 million.”
EPS — Initiated (“introducing”)
“The Company is introducing its fourth-quarter 2025 adjusted-diluted EPS guidance range of $1.81 to $1.86.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Capital expenditures were $209.8 million, a decrease of 22.9% over the same period last year.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Free cash flow (defined as operating cash flow minus capital expenditures) was $293.9 million, an increase of 53.7% over the same period last year.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
During the first nine months of 2025, the Company repurchased 552,593 shares for $134.0 million at an average share price of $242.55 under its share repurchase program.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Expected to drive 200 bps of revenue in FY25 GLP-1 elastomers are 9% of 3Q25 total company revenues GLP-1 Contract Manufacturing revenues are 8% of 3Q25 total company revenues CM future revenue growth/ margin expansion opportunity from drug handling Capex aligned to growth opportunities in biologics, Annex 1 and GLP-1 Network optimization: improving service levels/managing tariff exposure B u sin ess O p p o rtu n ity, Im p act & R esu lts D river 6 Proprietary Products Segment Segment Performance Proprietary net sales of $647.5M, +7.7% YoY, +5.1% organic Segment gross profit of 40.8%, +160 bps YoY Proprietary OP margin of 27.1%, +80 bps YoY.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
on Adjusted EPS Tax Benefits from Stock- Based Compensation Estimated Tax Rate Capital Expenditure Low High Low High Low High $3.040B $3.060B 3.0% 3.75% $6.65 $6.85 ~$59M Benefit +$0.27 +$0.04 $275M $3.060B $3.070B 3.75% 4.0% $7.06 $7.11 ~$59M Benefit +$0.27 +$0.05 $275M $790M $800M 1.0% 2.3% $1.81 $1.86 to to to to to to to to to Guidance Overview ~21% ~$35M Benefit +$0.14 ~20.5%~22% Investor Relations contact: https://investor.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
Strategy & priorities
3Q24 o $19 million, one-time incentive fee in PY negatively impacted YoY OP margin expansion by 200 bps Adj-diluted EPS(1) of $1.96, +5.9% vs.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
Diluted EPS +5.9% YoY-40 bps YoY +7.7% Reported +5.0% Organic 5 Capitalizing on Key Growth Drivers Across Our Business Biologics Expanding market driving High- Value Products Annex 1 EU regulatory framework upgrade opportunity GLP-1 Fastest growing category, multi-year opportunity 17% of Net Sales Capacity Expansion Across 8 locations: 4 in U.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
Expected to drive 200 bps of revenue in FY25 GLP-1 elastomers are 9% of 3Q25 total company revenues GLP-1 Contract Manufacturing revenues are 8% of 3Q25 total company revenues CM future revenue growth/ margin expansion opportunity from drug handling Capex aligned to growth opportunities in biologics, Annex 1 and GLP-1 Network optimization: improving service levels/managing tariff exposure B u sin ess O p p o rtu n ity, Im p act & R esu lts D river 6 Proprietary Products Segment Segment Performance Proprietary net sales of $647.5M, +7.7% YoY, +5.1% organic Segment gross profit of 40.8%, +160 bps YoY Proprietary OP margin of 27.1%, +80 bps YoY.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
Risks & headwinds
These statements reflect management s current expectations regarding future events, expected tax rates, impacts of tariffs, and operating performance and speak only as of the date of this release.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
These forward-looking statements involve a number of risks and uncertainties.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Expected to drive 200 bps of revenue in FY25 GLP-1 elastomers are 9% of 3Q25 total company revenues GLP-1 Contract Manufacturing revenues are 8% of 3Q25 total company revenues CM future revenue growth/ margin expansion opportunity from drug handling Capex aligned to growth opportunities in biologics, Annex 1 and GLP-1 Network optimization: improving service levels/managing tariff exposure B u sin ess O p p o rtu n ity, Im p act & R esu lts D river 6 Proprietary Products Segment Segment Performance Proprietary net sales of $647.5M, +7.7% YoY, +5.1% organic Segment gross profit of 40.8%, +160 bps YoY Proprietary OP margin of 27.1%, +80 bps YoY.
SEC original ↗West Pharmaceutical Services — Presentation / slide deck (8-K exhibit)EX-99Oct 23, 2025
What changed vs prior quarter
Guidance direction — prior quarter: Raised; this quarter: Raised
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
EPS — prior quarter passage and this quarter's passage are both cited.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Adjusted EPS — prior quarter passage and this quarter's passage are both cited.
SEC original ↗West Pharmaceutical Services — Earnings release (8-K exhibit)EX-99Oct 23, 2025
Earnings deck slides
0 decks with slide viewWest Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
West Pharmaceutical Services — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
67 documents- Q3 2026
- 8-KWST
- 10-QWST
- 8-KWST
- Q2 2026
- 10-QWST
- 8-KWST
- 8-KWST
- Q1 2026
- 8-KWST
- 8-K/AWST
- 8-KWST
- 8-KWST
- 10-QWST
- 8-KWST
- Q4 2025
- 8-KWST
- 10-KWST
- 8-KWST
- Q3 2025
- 10-QWST
- 8-KWST
- Q2 2025
- 8-KWST
- 10-QWST
- 8-KWST
- 8-KWST
- EX-99WST
- Q1 2025
- 8-K/AWST
- 8-KWST
- 10-QWST
- 8-KWST
- 8-KWST
- EX-99WST
- 8-KWST
- Q4 2024
- 8-KWST
- 10-KWST
- 8-KWST
- Q3 2024
- 8-KWST
- 8-KWST
- EX-99WST
- 10-QWST
- 8-KWST
- 8-KWST
- Q2 2024
- 8-KWST
- 10-QWST
- 8-KWST
- Q1 2024
- 8-KWST
- 8-KWST
- 10-QWST
- Q4 2023
- 10-KWST
- 8-KWST
- Q3 2023
- 8-KWST
- 8-KWST
- 10-QWST
- Q2 2023
- 8-K/AWST
- 8-KWST
- 10-QWST
- Q1 2023
- 8-KWST
- 8-KWST
- 10-QWST
- Q4 2022
- 10-KWST
- 8-KWST
- Q3 2022
- 8-KWST
- 10-QWST
- Q2 2022
- 8-KWST
- 10-QWST
- 8-KWST
- EX-99WST
- Q1 2022
- 8-KWST
- 8-KWST
- EX-99WST
- 10-QWST
Earnings releases
22 documents- Q3 2026
- EX-99WST
- Q2 2026
- EX-99WST
- Q1 2026
- EX-99WST
- EX-99WST
- EX-99WST
- Q4 2025
- EX-99WST
- EX-99WST
- Q3 2025
- EX-99WST
- Q2 2025
- EX-99WST
- Q1 2025
- EX-99WST
- Q4 2024
- EX-99WST
- Q3 2024
- EX-99WST
- EX-99WST
- Q2 2024
- EX-99WST
- Q1 2024
- EX-99WST
- Q4 2023
- EX-99WST
- Q3 2023
- EX-99WST
- Q2 2023
- EX-99WST
- Q1 2023
- EX-99WST
- Q4 2022
- EX-99WST
- Q3 2022
- EX-99WST
- Q2 2022
- EX-99WST
Presentations
17 documents
Transcripts
0 documentsNo transcripts for West Pharmaceutical Services are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.